Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43921077" target="_blank" >RIV/00216208:11120/21:43921077 - isvavai.cz</a>

Alternative codes found

RIV/75010330:_____/21:00013407 RIV/00216208:11110/21:10421859 RIV/00064211:_____/21:W0000029 RIV/00179906:_____/21:10421859

Result on the web

<a href="https://doi.org/10.1017/S0950268821000194" target="_blank" >https://doi.org/10.1017/S0950268821000194</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1017/S0950268821000194" target="_blank" >10.1017/S0950268821000194</a>

Result language

angličtina

Original language name

Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons

Original language description

Tick-borne encephalitis (TBE) is a vector-borne infection associated with a variety of potentially serious complications and sequelae. Vaccination against TBE is strongly recommended for people living in endemic areas. There are two TBE vaccination schemes - standard and rapid - which differ in the onset of protection. With vaccination in a rapid schedule, protection starts as early as four weeks after the first dose and is therefore especially recommended for non-immune individuals travelling to endemic areas. Both schemes work reliably in immunocompetent individuals, but only little is known about how TBE vaccination works in people with HIV infection. Our aim was to assess the immunogenicity and safety of the rapid scheme of TBE vaccination in HIV-1 infected individuals. Concentrations of TBE specific IgG&gt;126 VIEU/mL were considered protective. The seroprotection rate was 35.7% on day 28 and 39.3% on day 60. There were no differences between responders and non-responders in baseline and nadir CD4+ T lymphocytes. No serious adverse events were observed after vaccination. The immunogenicity of the TBE vaccination was unsatisfactory in our study and early protection was only achieved in a small proportion of vaccinees. Therefore, TBE vaccination with the rapid scheme cannot be recommended for HIV-1 infected individuals.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30303 - Infectious Diseases

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Epidemiology &amp; Infection

ISSN

0950-2688

e-ISSN

—

Volume of the periodical

149

Issue of the periodical within the volume

January

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

"e41"

UT code for WoS article

000618081400001

EID of the result in the Scopus database

2-s2.0-85100078995